Provided by Tiger Trade Technology Pte. Ltd.

Hillhouse Capital Holdings

4,792.84
+57.881.22%
Number of Gainers:22
Number of Losers:41
Number of Flat:2
PE:- -
High:4,820.40
Open:4,734.89
Low:4,711.32
Close:4,734.96
Volume:370.74M
Turnover:34.88B
Market Cap:8.56T
Float Cap:8.10T

Loading ...

Stocks to Watch: Meta, Nvidia, Kohl's

Dow Jones
·
Aug 26

Post-95s Young Farmer Cultivates Success: Xia County Watermelons Rise to National Fame Through E-commerce

Deep News
·
Aug 26

XPeng Price Target Cut to $14.00/Share from $15.00 by Barclays

Dow Jones
·
Aug 26

Nvidia, Meta, Intuit, Salesforce, Zoom, Kohl's, and More Stocks That Explain Today's Market

Dow Jones
·
Aug 26

Salesforce (CRM) Earnings Preview: Can AI Growth Unlock 16% Upside?

TIPRANKS
·
Aug 26

Alibaba Unveils Open-Source Qwen3.8-Flash, Outperforming Opus4.6 at Just 3% of the Cost

Deep News
·
Aug 26

NIO Q2 Earnings Preview: What Investors Should Know Ahead of September 1

TIPRANKS
·
Aug 26

UiPath announces Banco Azteca transformed automation program using Maestro

TIPRANKS
·
Aug 26

Miniso Group Holding Ltd Expected to Post Earnings of Cny2.12 a Share - Earnings Preview

Reuters
·
Aug 26

U.S. Stocks on the MOVE-Semtech, Donaldson, Meta

Reuters
·
Aug 26

Why Is Zoom Stock Sliding On Wednesday?

Benzinga Earnings
·
Aug 26

BridgeBio Pharma Doses First Patient in Trial Evaluating Long-Term Impact of Heart Disease Medicine

MT Newswires Live
·
Aug 26

Salesforce Last-Minute Q2 Earnings Alert: Options Traders Expect a 7.38% Move in CRM Stock

TIPRANKS
·
Aug 26

Zoom Communications delivered decent Q2 results, says RBC Capital

TIPRANKS
·
Aug 26

Rapid Revenue Surge in Data Observability Startups Driven by AI Agent Boom

Deep News
·
Aug 26

Alibaba Raises HK$80 Billion in Hong Kong Share Placement to Fund AI and Cloud Expansion

TIPRANKS
·
Aug 26

Stock Spirits Names Paola Agasso as Group CFO

Reuters
·
Aug 26

BridgeBio Pharma doses first patient in ASCEND-ATTR trial

TIPRANKS
·
Aug 26

US Companies Face Rise in Cyber Attacks

Reuters
·
Aug 26

BridgeBio Announces First Participant Dosed in Ascend-Attr, a Phase 3B/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in Attr-Cm

THOMSON REUTERS
·
Aug 26